Christine Fox sold $700k of TEVA
EVP, Head of U.S. Commercial at TEVA PHARMACEUTICAL INDUSTRIES LTD. 28,229 shares at an average of $24.78, traded Nov 20, 2025, filed Nov 24, 2025.
Score components
- +15RoleOfficer
- +21Trade size$700k at market
- +10Share of holdings soldSold 31% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-293655, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 20, 2025 | MOption exercise Ordinary Shares10b5-1 | +63,492 | - | - | 91,876 | Nov 24, 2025 |
| Nov 20, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -28,229 | $24.78 | $700k | 63,647 | Nov 24, 2025 |
| Nov 20, 2025 | MOption exercise Restricted Share Unitsderivative10b5-1 | -63,492 | $0.00 | $0 | 126,984 | Nov 24, 2025 |
Related signals
Other insiders at TEVA PHARMACEUTICAL INDUSTRIES LTD and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 68Notable | TEVA PHARMACEUTICAL INDUSTRIES LTD | Roberto Mignone director | $14M 367,600 shares | -100% | |
| 32Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Brian Savage Interim Chief Legal Officer | $285k 7,342 shares | -46% | |
| 60Notable | TEVA PHARMACEUTICAL INDUSTRIES LTD | Roberto Mignone director | $2.3M 77,400 shares | -17% | |
| 65Notable | TEVA PHARMACEUTICAL INDUSTRIES LTD | Amir Weiss Chief Accounting Officer | $372k 12,300 shares | -69% | |
| 60Notable | TEVA PHARMACEUTICAL INDUSTRIES LTD | Richard Daniell Exec. VP, European Commercial | $3.3M 115,468 shares | -70% | |
| 60Notable | TEVA PHARMACEUTICAL INDUSTRIES LTD | Mark Sabag See "Remarks" | $6.2M 216,892 shares | -80% | |
| 60Notable | TEVA PHARMACEUTICAL INDUSTRIES LTD | Roberto Mignone director | $1.3M 50,000 shares | -10% | |
| 72Notable | TEVA PHARMACEUTICAL INDUSTRIES LTD | Christine Fox EVP, Head of U.S. Commercial | $753k 30,000 shares | -51% | |
| 65Notable | TEVA PHARMACEUTICAL INDUSTRIES LTD | Roberto Mignone director | $4.8M 200,000 shares | -29% | |
| 54Moderate | TEVA PHARMACEUTICAL INDUSTRIES LTD | Amir Weiss Chief Accounting Officer | $301k 12,300 shares | -41% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.